BUHLMANN News

The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease

BÜHLMANN fCAL® ELISA Citation Zhulina, Y. et al., 2016, The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease, Aliment Pharmacol Ther.  PMID: 27402063 DOI: 10.1111/apt.13731 Highlight from this Publication “Our data suggest that longitudinal monitoring of faecal calprotectin is informative in predicting relapse in IBD.“ Read Citation BÜHLMANN fCAL® ELISA is FDA 510(k) cleared For in vitro Diagnostic
Continue Reading

Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease

Quantum Blue® fCAL Citation: Ferreiro-Iglesias, R., Barreiro-de Acosta, M., Lorenzo-Gonzalez, A. & Dominguez-Muñoz, J. E. Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease Patients Under Maintenance With Anti-TNF Therapy: A Prospective Longitudinal Cohort Study. J. Clin. Gastroenterol. (2016) PMID: remission, whereas concentrations >300 μg/g allow predicting relapse with a high probability at any
Continue Reading

Evaluation of S100 Proteins As Potential Biomarkers of Global and Renal-Specific Disease Activity in Childhood-Onset Systemic Lupus Erythematosus

BÜHLMANN sCAL ELISA: Turnier J et al.: Evaluation of S100 Proteins as Potential Biomarkers of Global and Renal-Specific Disease Activity in Childhood-Onset Systemic Lupus Erythematosus. Poster presented at ACR/ARHP, 2016: November 11-16, Washington, DC (USA). View Poster BÜHLMANN sCAL ELISA is for Research Use Only.  Not for use in diagnostic procedures in the US and
Continue Reading

Biomarkers as predictors of flares in inflammatory bowel disease

BÜHLMANN sCAL ELISA: Lavric M et al.: Biomarkers as Predictors of Flares in Inflammatory Bowel Disease. Poster presented at final MIAMI Meeting (Translating Science into targets); 2016: April 13-15, Muenster (Germany). View Poster BÜHLMANN sCAL ELISA is for Research Use Only.  Not for use in diagnostic procedures in the US and Canada.
Continue Reading

Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein

BÜHLMANN sCAL ELISA: Hurnakova J et al.: Serum Calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein.  Poster presented at EULAR; 2017: June 14-17, Madrid (Spain). PMID: 29656372  DOI: 10.1007/s10067-018-4091-5 Read Citation BÜHLMANN sCAL ELISA is for Research Use Only.  Not for use in diagnostic procedures in the US and
Continue Reading

Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study

BÜHLMANN sCAL ELISA: Hurnakova J et al.: Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study. PLoS ONE, 2017: 12(8): 1-11.  PMID: 28832684  doi:  10.1371/journal.pone.0183420 Read Citation BÜHLMANN sCAL ELISA is for Research Use Only.  Not for use in diagnostic procedures in the US and Canada.
Continue Reading

Measurement of blood calprotectin (MRP-8/MRP-14) levels in patients with juvenile idiopathic arthritis

BÜHLMANN sCAL ELISA: Bojko J et al.: Measurement of blood calprotectin (MRP-8/MRP-14) levels in patients with juvenile idiopathic arthritis.  Rheumatologia, 2017: 55(1): 10-14.  PMID: 28386137  doi:  10.5114/reum.2017.66682 Read Citation BÜHLMANN sCAL ELISA is for Research Use Only.  Not for use in diagnostic procedures in the US and Canada.
Continue Reading

Low pretreatment levels of myeloid-related protein-8/14 and C-reactive protein predict poor adherence to treatment with tumor necrosis factor inhibitors in juvenile idiopathic arthritis

BÜHLMANN sCAL ELISA: Albredi-Saugstrup M et al.: Low pretreatment levels of myeloid-related protein 8/14 and C-reactive protein predict poos adherence to treatment with tumor necrosis factor inhibitors in juvenile idiopathic arthritis.; Clinical Rheumatology: 2017: 36(1), 67-75.  PMID: 27562034 DOI: 10.1007/s10067-016-3375-x Read Citation BÜHLMANN sCAL ELISA is for Research Use Only.  Not for use in diagnostic procedures in the US
Continue Reading

Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis

BÜHLMANN sCAL ELISA: Levitova A et al.: Clinical Improvement and Reduction in serum calprotectin levels after an intensive exercise programme for patients with AS and non-radiographic spondyloarthritis; Arthritis Research and Therapy: 2016: 18(1): 275.  PMID: 27887637  doi:  10.1186/s13075-016-1180-1 Read Citation BÜHLMANN sCAL ELISA is for Research Use Only.  Not for use in diagnostic procedures in the US and Canada.
Continue Reading

Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission

BÜHLMANN sCAL ELISA: Hurnakova J et al.: Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound- Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission; PLoS One; 2016: e0165498.  PMID: 27832086  DOI: 10.1371/journal.pone.0165498 Read Citation BÜHLMANN sCAL ELISA is for Research Use Only.  Not for use in diagnostic procedures in the US and Canada.
Continue Reading